Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M40,123Revenue (TTM) $M12,482Net Margin (%)7.8Altman Z-Score2.8
Enterprise Value $M49,714EPS (TTM) $4.5Operating Margin %11.5Piotroski F-Score6
P/E(ttm)38.5Beneish M-Score-2.8Pre-tax Margin (%)8.6Higher ROA y-yN
Price/Book4.810-y EBITDA Growth Rate %5.6Quick Ratio1.1Cash flow > EarningsY
Price/Sales3.05-y EBITDA Growth Rate %3.0Current Ratio1.5Lower Leverage y-yY
Price/Free Cash Flow20.4y-y EBITDA Growth Rate %22.8ROA % (ttm)3.7Higher Current Ratio y-yY
Dividend Yield %1.6PEG12.8ROE % (ttm)12.9Less Shares Outstanding y-yN
Payout Ratio %59.0Shares Outstanding M231ROIC % (ttm)7.8Gross Margin Increase y-yY

Gurus Latest Trades with BDX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BDXT Rowe Price Equity Income Fund 2016-12-31 Add0.01%$162.8 - $179.19
($170.13)
$ 173.522%Add 1.44%984,000
BDXKen Fisher 2016-12-31 Add$162.8 - $179.19
($170.13)
$ 173.522%Add 26.26%1,760
BDXRobert Olstein 2016-09-30 Reduce-0.23%$169.64 - $181.55
($175.28)
$ 173.52-1%Reduce -21.52%36,100
BDXVanguard Health Care Fund 2016-09-30 Reduce-0.2%$169.64 - $181.55
($175.28)
$ 173.52-1%Reduce -30.33%1,301,633
BDXFirst Eagle Investment 2016-09-30 Sold Out -0.17%$169.64 - $181.55
($175.28)
$ 173.52-1%Sold Out0
BDXT Rowe Price Equity Income Fund 2016-09-30 Add0.09%$169.64 - $181.55
($175.28)
$ 173.52-1%Add 12.79%970,000
BDXJoel Greenblatt 2016-09-30 Sold Out -0.04%$169.64 - $181.55
($175.28)
$ 173.52-1%Sold Out0
BDXMario Gabelli 2016-09-30 Reduce-0.03%$169.64 - $181.55
($175.28)
$ 173.52-1%Reduce -16.55%135,909
BDXKen Fisher 2016-09-30 Reduce$169.64 - $181.55
($175.28)
$ 173.52-1%Reduce -0.07%1,394
BDXFirst Eagle Investment 2016-06-30 Reduce-0.39%$151.82 - $172.19
($163.71)
$ 173.526%Reduce -71.89%390,407
BDXVanguard Health Care Fund 2016-06-30 Reduce-0.28%$151.82 - $172.19
($163.71)
$ 173.526%Reduce -30.89%1,868,387
BDXRobert Olstein 2016-06-30 Reduce-0.16%$151.82 - $172.19
($163.71)
$ 173.526%Reduce -14.81%46,000
BDXT Rowe Price Equity Income Fund 2016-06-30 Add0.1%$151.82 - $172.19
($163.71)
$ 173.526%Add 17.47%860,000
BDXMario Gabelli 2016-06-30 Reduce-0.03%$151.82 - $172.19
($163.71)
$ 173.526%Reduce -14.77%162,864
BDXKen Fisher 2016-06-30 Reduce$151.82 - $172.19
($163.71)
$ 173.526%Reduce -5.30%1,395
BDXJoel Greenblatt 2016-06-30 Reduce$151.82 - $172.19
($163.71)
$ 173.526%Reduce -4.40%18,713
BDXDodge & Cox 2016-06-30 Reduce$151.82 - $172.19
($163.71)
$ 173.526%Reduce -7.37%13,830
BDXT Rowe Price Equity Income Fund 2016-03-31 Add0.27%$132.88 - $154.09
($145.43)
$ 173.5219%Add 104.61%732,099
BDXRobert Olstein 2016-03-31 Reduce-0.22%$132.88 - $154.09
($145.43)
$ 173.5219%Reduce -16.92%54,000
BDXJoel Greenblatt 2016-03-31 Reduce-0.1%$132.88 - $154.09
($145.43)
$ 173.5219%Reduce -75.23%19,575
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BDX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Gallagher John EVP, Corp Finance and Treasurer 2016-12-15Sell1,793$168.822.78view
Sichak StephenExecutive Vice President 2016-12-05Sell2,632$164.445.52view
Sichak StephenExecutive Vice President 2016-11-04Sell10,352$176.1-1.47view
Tharby Linda MExecutive Vice President 2016-09-06Sell11,704$177.27-2.12view
COHEN GARY MExecutive Vice President 2016-08-11Sell29,367$176.81-1.86view
Gallagher John EVP, Corp Finance and Treasurer 2016-06-13Sell1,931$169.872.15view
Shabshab NabilExecutive Vice President 2016-06-07Sell5,080$168.752.83view
SHERMAN JEFFREY SSr. VP and General Counsel 2016-05-17Sell34,373$166.274.36view
FORLENZA VINCENT AChairman, CEO and President 2016-05-13Sell37,933$166.174.42view
Sichak StephenExecutive Vice President 2016-05-13Sell12,995$166.484.23view

Press Releases about BDX :

Quarterly/Annual Reports about BDX:

News about BDX:

Articles On GuruFocus.com
5 Stocks to Avoid - January 2017 Jan 14 2017 
Top 7 Dividend Health Care Stocks Jan 05 2017 
The 10 Best Dividend Aristocrats for 2017 and Beyond Dec 23 2016 
Becton Dickinson Lifts Dividend by 11% Nov 30 2016 
A Growth Stock in the Land of Value Stocks? Nov 30 2016 
Dividend Aristocrats in Focus Part 26: Becton, Dickinson and Co. Nov 02 2016 
Numerous Companies Reach Yearly Highs Oct 03 2016 
The 10 Best Dividend Aristocrats Aug 15 2016 
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Aug 02 2016 
Mawer Investment Newsletter 2nd Quarter 2016 Jul 15 2016 

More From Other Websites
BECTON DICKINSON & CO Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 19 2017
BD Announces Webcast of Annual Meeting of Shareholders Jan 18 2017
Becton, Dickinson Commercially Launches Precise WTA Kits Jan 18 2017
BD Launches Reagents to Simplify Single Cell Research Jan 17 2017
Becton, Dickinson & Co. – Value Analysis (NYSE:BDX) : January 11, 2017 Jan 11 2017
Post Earnings Coverage as AngioDynamics Adjusted EPS Soared 36% Jan 11 2017
BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call Jan 11 2017
Becton, Dickinson & Co. breached its 50 day moving average in a Bullish Manner : BDX-US : January... Jan 10 2017
BD to Present at the 35th Annual J. P. Morgan Healthcare Conference Jan 09 2017
Top 7 Dividend Health Care Stocks Jan 05 2017
How Do Wall Street Analysts View Becton Dickinson? Jan 05 2017
Becton Dickinson downgraded by Raymond James Jan 05 2017
A Look at Becton Dickinson’s Recent Stock Performance Jan 04 2017
Inside Becton Dickinson’s Financial Guidance for 2017 Jan 04 2017
10 Great All-Weather Stocks Jan 04 2017
BD’s Latest Dividend Payment and Capital Allocation Strategy Jan 04 2017
A Look at BDX’s Recent Product Launches Jan 03 2017
Analyzing the BD Medical Segment’s Product Pipeline Jan 03 2017
BD’s Medical Segment Performance and Growth Strategy Jan 03 2017
BD Lifesciences’s Product Pipeline Could Boost Its Fiscal 2017 Growth Jan 02 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)